Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas H Scheel

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.
Archives of Pathology & Laboratory Medicine|August 7, 2024
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast CancerJosef Rüschoff, Alexander Penner, Ian O Ellis, et al.
Pathology, Research and Practice|November 8, 2017
EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP<sup>®</sup>)Iver Petersen, Manfred Dietel, Wolf J Geilenkeuser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2016
Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung CancerJulie George, Motonobu Saito, Koji Tsuta, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Lung Cancer (Amsterdam, Netherlands)|April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsMatthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Histopathology|August 30, 2017
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancerAndreas H Scheel, Gudrun Baenfer, Gustavo Baretton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Oncoimmunology|July 29, 2016
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterationsAndreas H Scheel, Sascha Ansén, Anne M Schultheis, et al.
Archives of Pathology & Laboratory Medicine|August 7, 2024
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast CancerJosef Rüschoff, Alexander Penner, Ian O Ellis, et al.
Pathology, Research and Practice|November 8, 2017
EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC - Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP<sup>®</sup>)Iver Petersen, Manfred Dietel, Wolf J Geilenkeuser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2016
Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung CancerJulie George, Motonobu Saito, Koji Tsuta, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Lung Cancer (Amsterdam, Netherlands)|April 23, 2022
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implicationsMatthias Scheffler, Marcel Wiesweg, Sebastian Michels, et al.
Histopathology|August 30, 2017
Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancerAndreas H Scheel, Gudrun Baenfer, Gustavo Baretton, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2017
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma PatientsDennis Plenker, Miriam Bertrand, Adrianus J de Langen, et al.
Cancer Immunology Research|October 11, 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGFMariangela Di Tacchio, Jadranka Macas, Jakob Weissenberger, et al.
Pageof 5